A Phase III Randomized Study to Evaluate the Efficacy of Zometa for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer.

Trial Profile

A Phase III Randomized Study to Evaluate the Efficacy of Zometa for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Zoledronic acid (Primary) ; Buserelin; Calcium carbonate; Calcium citrate; Calcium gluconate; Colecalciferol; Goserelin; Leuprorelin; Triptorelin
  • Indications Fracture; Osteoporosis; Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 06 Nov 2010 Planned end date added to 1 Dec 2020 as reported by ClinicalTrials.gov record.
    • 05 Oct 2009 Additional lead investigator (Smith G) added as reported by New Jersey Cancer Trial Connect record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top